我们的希望在这里……-->特深沉转移

lxx00630

干扰乙肝病毒 2003年6月 《nature--biotechnology》 6月份的《自然-生物技术》报告说，在斯坦福大学医学院Mark Kay的领导下，一个科学家小组证明，用一个很小的RNA片段去抑制肝脏中的病毒特异性RNA，能够遏制乙肝病毒在小鼠体内的发展进程。该实验首次采用小分子干扰RNA(siRNA)来抑制动物体内的病毒感染。研究人员向小鼠尾部注射了一种以肝炎病毒为作用目标的siRNA，干扰了乙肝病毒的复制和增殖。这种siRNA分子的设计目的就是与肝细胞中2个乙肝病毒RNA进行特异性结合，并经过一系列复杂过程，最终干扰乙肝病毒的复制。这种方法使乙肝表面抗原(HBsAg)减少了84.5%，乙肝病毒核心抗原(HBcAg)则减少了99%以上。作为一种可供选择的疗法，这种方法不仅给乙肝，而且给其他类型的病毒感染带来了希望。 Interfering with Hepatitis B Scientists have developed a strategy for treating hepatitis B infection, which affects several hundred million people worldwide and can lead to chronic liver diseases such as cirrhosis and cancer. Although hepatitis B can be effectively prevented through immunization, once an individual is infected with the virus, currently available therapeutics are of only limited effectiveness. Reporting in the June issue of Nature Biotechnology, a group of scientists led by Mark Kay at the Stanford University School of Medicine show that progression of the hepatitis B virus in mice can be effectively contained by inactivating virus-specific RNA in the liver using a tiny piece of ribonucleic acid. The research is the first time small interfering ribonucleic acid molecules (siRNAs) have been used to curb a viral infection in an animal. By injecting an siRNA that targets hepatitis virus into the tails of mice, the researchers were able to disrupt hepatitis B virus replication and proliferation. The siRNA molecules were designed to specifically bind to two hepatitis B virus RNAs in the liver cells and, following a complex chain of events, ultimately interfere with hepatitis B virus replication. The approach resulted in an 84.5% reduction in hepatitis B virus surface antigen (HBsAg) and a >99% reduction in the hepatitis B virus core antigen (HBcAg). The approach holds promise as a therapeutic option not only for hepatitis B but also for other types of viral infections. [此贴子已经被作者于2003-8-23 23:08:10编辑过] ---------------------------------------------- Don't judge everyday only by the harvest you reap, but the seeds you plant. 我的HBV记 >>>打假黑名单<<< >>>维权资料与权益版目录<<<

lxx00630

以上是清照在学术讨论上贴的译文

lxx00630

自然-生物技术》：RNA干扰素对HBV复制的抑制

RNA Interference Inhibits HBV Replication

By Karla Gale

Hepatitis B (HBV) viral RNA interference reduced the ability of HBV to replicate in mice, scientists in California report in the advance issue of Nature Biotechnology, published online May 12.

"We have worked for 10 years on gene therapies for hepatitis, and this is the first that I believe really looks promising," senior author Dr. Mark A. Kay of Stanford University School of Medicine, California, told Reuters Health.

RNA interference can inhibit viral replication in cell culture and target viral sequences in vivo, but thus far no one has shown the ability of this technique to prevent viral replication in vivo, Dr. Kay and associates explain.

When they transfected cultured human hepatoma cells with plasmids expressing one of seven short hairpin RNAs (shRNA) directed against sequences conserved among major HBV genotypes, all but one significantly reduced the amount of HBV surface antigen in culture. The most effective shRNA reduced antigen expression by 94.2% after 8 days.

The researchers transfected mice with the plasmid that most reduced HBV surface antigen in culture. In immunocompetent mice, treatment resulted in 77% less HBV RNA transcripts in liver compared to controls, while RNA was reduced 92% in immunocompromised mice. Treatment reduced replicated HBV DNA to undetectable levels.

The differences between immunocompetent and immunocompromised mice were "not substantial," Dr. Kay said. However, "there is the possibility of a synergistic effect between the host immune response and shRNA," he added.

In mice lacking B and T lymphocytes, plasmid treatment reduced serum levels of HBV surface antigen by 88% at day 4.

Dr. Kay said that he does not expect that an immune response would be generated to interfering RNA, and his group observed no obvious toxicity in plasmid-treated mice.

He suggested three possible scenarios for RNA silencing in hepatitis B infection. "In the best scenario, the body is purged of virus and cured." Another possibility is a significant reduction in viral load, "which may buy someone 20 or 30 more years before developing liver disease."

He also believes that combining RNA interference treatment with drug therapy would provide a synergistic effect.

"In theory, any viral disorder" could be treated in this manner, he added, noting that another research group is experimenting with RNA silencing for treatment of HIV.

He and his associates now plan to transfect small mammals using viral vectors instead of plasmids. If successful, "I think 2 to 3 years would be a reasonable time frame" for initiating phase I trials in humans.

Nature? Biotechnology 2003.


----------------------------------------------
Hbvers of all countries,unite!

mammon

关键时刻，还是要看老外的啊。

sunday

黑夜中的希望

stones40

以下是引用lycjx在2002-9-17 14:39:00的发言：
我对国外的一些科研机构还是比较有信心的，期待奇迹出现

期待中！

好好好

还是老鼠好

bitpretty

不管中国大夫还是外国大夫，只要能治好乙肝就是好大夫！

特深沉

希望帮忙转移到学术交流版。

谢谢